Matrix Capital Management Company’s Trillium Therapeutics Inc. TRIL Stock Holding History

Matrix Capital Management Company’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,288,560	Closed	-$704K	–	25
2019 Q3	$704K	Hold	2,288,560	–	–	0.02%	23
2019 Q2	$753K	Hold	2,288,560	–	–	0.01%	24
2019 Q1	$1.51M	Hold	2,288,560	–	–	0.04%	20
2018 Q4	$3.91M	Hold	2,288,560	–	–	0.13%	19
2018 Q3	$13.3M	Hold	2,288,560	–	–	0.33%	21
2018 Q2	$13.7M	Buy	2,288,560 +36,554	+2%	+$233K	0.39%	20
2018 Q1	$16.2M	Buy	2,252,006 +79,006	+4%	+$599K	0.56%	21
2017 Q4	$15.8M	Buy	+2,173,000	New	+$18M	0.56%	18

Other funds holding TRIL

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Matrix Capital Management Company's TRIL Position: Q4 2019 in Review

Matrix Capital Management Company sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2019, closing a stake of 2,288,560 shares — an estimated $704K sold.

Matrix Capital Management Company first reported a position in TRIL in Q4 2017 and held it in 8 quarters. The position peaked at $16.2M in Q1 2018. 19 funds tracked by Wall St. Rank hold TRIL as of Q4 2019.

Matrix Capital Management Company reported no remaining Trillium Therapeutics Inc. position as of Q4 2019 after selling out during the quarter.
Matrix Capital Management Company sold 2,288,560 Trillium Therapeutics Inc. shares in Q4 2019, an estimated $704K.
Matrix Capital Management Company first reported a position in Trillium Therapeutics Inc. in Q4 2017 and held it in 8 quarters.
Matrix Capital Management Company's Trillium Therapeutics Inc. position peaked at $16.2M in Q1 2018.
19 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2019.

Based on Matrix Capital Management Company's 13F filing for Q4 2019, filed 14 Feb 2020.